Methods This retrospective, database study used Optums de-identified Clinformatics Data Mart Database to identify glucagon-like peptide 1 receptor agonist (GLP-1 RA) treatment-nave adult patients with type 2 diabetes (T2D) initiating semaglutide QW, dulaglutide, liraglutide, or exenatide QW between January 1, 2018 and April 30, 2019
Supportive secondary endpoints were not included in the statistical testing hierarchy and were: achievement of weight loss of 20% at week 104
This research demonstrates that caregivers are willing to accept risk in exchange for a five-point improvement on the HQ-CT, a smaller marginal improvement than had been previously classified as meaningful
Exendin-4 (Exenatide) mimicks GLP-1 but is much more potent in vivo following parenteral administration (28)
After primary discontinuation, the median follow-up time was 435 days (IQR, 271-730 days), with 25 483 of 41 792 patients (61.0%) followed up for at least 1 year and 10 483 of 41 792 patients (25.1%) followed up for at least 2 years
